Where is V-Wave located?

V-Wave is headquartered in Caesarea, Israel.

How many employees does V-Wave have?

As of Jan 23, 2025, the latest employee count at V-Wave is 71.

Is V-Wave a funded company?

V-Wave is a funded company, having raised a total of $132M across 5 funding rounds to date. The company's 1st funding round was a $***** Series A round.

When was the latest funding round of V-Wave?

V-Wave's latest funding was a $***** Series C round on Sep 23, 2020, with participation from 11 investors.

Where does V-Wave rank among its competitors?

V-Wave ranks 10th amongst 101 active competitors, of which 58 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Berlin Heals, which secured $10M in Feb, 2026.

Who are the top competitors of V-Wave?

V-Wave's top competitors include CVRx, Impulse Dynamics and CorWave. Among them, Berlin Heals secured the most recent funding round in February, 2026.

V-Wave - 2026 Company Profile, Team, Funding & Competitors

Q: Is V-Wave an acquired company?

V-Wave got acquired by Johnson & Johnson on Aug 20, 2024.

Company Details

V-Wave develops percutaneous implantable devices for treating patients with chronic Heart Failure. The compnay offers products like human implantable an inter-atrial shunt aimed at relieving symptoms and treating heart failure by controlling the left atrial pressure. The product is FDA approved.

Website: vwavemedical.com
Social

Key Metrics

Founded Year

2009

Location

Caesarea, Israel

Stage

Acquired

Total Funding

$132M in 5 rounds

Latest Funding Round

Series C, Sep 23, 2020, $*****

Investors

Deerfield & 13 more

Ranked

10^th among 101 active competitors

Employee Count

71 as on Jan 23, 2025

Similar Companies

CVRx & 127 more

Exit Details

Acquired by Johnson & Johnson (Aug 20, 2024)

View V-Wave's full profile

V-Wave got acquired by Johnson & Johnson on Aug 20, 2024 at an acquisition amount of $*****.

Click here to take a look at V-Wave's acquisition in detail

V-Wave has raised a total funding of $132M over 5 rounds. Its latest funding round was a Series C round on Sep 23, 2020 for $*****. 11 investors participated in its latest round. V-Wave has 14 institutional investors.

Here is the list of recent funding rounds of V-Wave:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 23, 2020	9428036	Series C	8132023	6642921	9977141	7731779
2017	4879	Series C	1510	4069	2693	Endeavour Vision & 9 more
Jan 11, 2016	1890432	Series B	3300898	2550628	Pura Vida Investments & 3 more	Edwards Lifesciences & 2 more

Access funding benchmarks and valuations. Sign up today!

View details of V-Wave's funding rounds and investors

V-Wave's employee count trend

V-Wave has 71 employees as of Jan 25. Here is V-Wave's employee count trend over the years:

Uncover V-Wave's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of V-Wave include CVRx, Impulse Dynamics and CorWave. Here is the list of Top 10 competitors of V-Wave, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	CVRx 2001, Minneapolis (United States), Public	Developer of implantable technology for hypertension and heart failure	$394M	Johnson & Johnson Innovation – JJDC, New Enterprise Associates ... & 20 others	68/100
2nd	Impulse Dynamics 1998, Marlton (United States), Series F	Provider of implantable device for treatment of chronic heart failure	$685M	Perceptive Advisors, Redmile Group & 16 others	64/100
3rd	CorWave 2011, Paris (France), Series C	Developer of implantable blood pumps for the treatment of heart failure	$127M	Novo Holdings, Exor Ventures & 11 others	61/100
4th	Element Science 2013, San Francisco (United States), Series C	Wearable therapeutic device for treating sudden cardiac arrest	$193M	Deerfield, Qiming & 4 others	61/100
5th	SynCardia 2001, Tucson (United States), Public	Artificial heart	$72M	Athyrium Capital Management, SWK Holdings ... & 5 others	60/100
6th	Restore Medical 2016, Tel Aviv (Israel), Series B	Catheter-delivered implant for treatment of congestive heart failure	$32M	European Innovation Council, Pitango & 3 others	57/100
7th	FineHeart 2010, Pessac (France), Series C	Developer of an implantable cardiovascular device for treating heart failures	$51.9M	Verve Ventures, Broadview Ventures & 16 others	57/100
8th	Procyrion 2005, Houston (United States), Series E	Developing percutaneous mechanical circulatory support for heart failure and cardiorenal syndrome	$114M	Fannin Innovation Studio, Scientific Health Development ... & 4 others	56/100
9th	Berlin Heals 2010, Zug (Switzerland), Series B	Developer of a microcurrent device for heart failure treatment. This device is a novel cardiac implant that provides a minimal electrical direct current to the heart, promoting reverse remodeling of cardiac muscle tissue. The treatment has shown rapid improvements in heart function, size, and quality of life in clinical studies. The device is easily implantable and requires no additional medication or follow-up procedures. The company is currently conducting clinical studies to obtain regulatory approvals.	$34.6M	BLR Partners	51/100
10th	V-Wave 2009, Caesarea (Israel), Acquired	Provider of implantable shunt to treat heart failure	$132M	Deerfield, Endeavour Vision & 12 others	48/100